About Orphan Technologies
Orphan Technologies is a Healthcare company based in Lexington (United States) founded in 2010, and was acquired by Retrophin in October 2020. Enzyme replacement therapy for homocystinuria is being developed. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its competitors include BridgeBio, Moderna and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Orphan Technologies was founded in 2010 and is based in Lexington, United States. Focus is placed on biotechnology for rare diseases, with operations centered on enzyme replacement therapies. The lead candidate, OT-58, consists of a recombinant enzyme intended for homocystinuria treatment and remains in pre-clinical trials. Development efforts target unmet needs in metabolic disorders through targeted enzymatic interventions.
- Headquarters Lexington, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website orphantechnologies.com
- Acquired by Retrophin (Oct 2020)
Investors in Orphan Technologies
Orphan Technologies has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Retrophin.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drugs are developed for debilitating and life-threatening diseases. | 2011 | retrophin.com | San Diego, United States |
Investor details for Orphan Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Orphan Technologies
2 dated milestones of Orphan Technologies across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Orphan Technologies is founded.
- Exit Acquired by Retrophin.
Competitors of Orphan Technologies
Orphan Technologies has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Moderna and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Orphan Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Orphan Technologies (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Orphan Technologies
Complete news archive for Orphan Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orphan Technologies
Orphan Technologies was founded in 2010.
Orphan Technologies is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Orphan Technologies was founded in 2010 and is based in Lexington, United States. Focus is placed on biotechnology for rare diseases, with operations centered on enzyme replacement therapies. The lead candidate, OT-58, consists of a recombinant enzyme intended for homocystinuria treatment and remains in pre-clinical trials. Development efforts target unmet needs in metabolic disorders through targeted enzymatic interventions.
Orphan Technologies's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Orphan Technologies has 1 investor. Key investors include Retrophin.
Yes. Orphan Technologies was acquired by Retrophin in October 2020.

